For this reason, these two genes are now potential targets for anticancer therapies such as cetuximab and trastuzumab (anti-CRC drugs) and anti-EGFR and HER-2 monoclonal antibodies, which are already available on the market. The gene discussed is EGFR; the disease is colorectal carcinoma.